1RO Validation of a prognostic circulating immune protein signature and exploratory dynamic biomarker analyses from the phase III ANITA (ENGOT-Ov41/GEICO 69-O) trial in recurrent ovarian cancer (OC)
Previously we developed a signature combining 4 baseline (BL) circulating immune-oncology proteins and 4 clinical variables to predict overall survival (OS) in ANITA [ESMO 2025]. Here we report signature validation and exploratory longitudinal analyses.
Authors
- MJ Rubio Pérez
- M.J. Bermejo‐Pérez
- F. Heitz
- A. González-Martín
- T. van Gorp
- C. Lebreton
- A.M. Santaballa Bertran
- P Wimberger
- A. Redondo
- F. Kridelka
- R. Armananzas
- L. Gaba Garcia
- M.P. Barretina Ginesta
- V. Zizioli
- A. Oaknin
- A. Leary
- B. Tavira
- J. González-Gomariz
- I.L. Ray-Coquard
- L.M. De Sande González
Institutions
- Universitat de Girona (ES)
- Catalan Institute for Water Research (ES)
- Universitair Ziekenhuis Leuven (BE)
- Hospital Universitario La Paz (ES)
- Institut Gustave Roussy (FR)
- Hospital Universitari i Politècnic La Fe (ES)
- The European Academy of Gynaecological Surgery (BE)
- Clínica Girona (ES)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Centre Léon Bérard (FR)
- Institut Català d'Oncologia (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Universitario Reina Sofía (ES)
- Institut Bergonié (FR)
- Centre Hospitalier Universitaire de Liège (BE)
- Clinica Universidad de Navarra (ES)
- Kliniken Essen-Mitte (DE)
- Spanish Ovarian Cancer Research Group (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Hospital Universitario de León (ES)
- Technische Universität Dresden (DE)
- Universidad de Navarra (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108026
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00